Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.
Xiang YJ, Liu ZH, Feng JK, Qin YY, Yu HM, Cheng YQ, Chen G, Wu JY, Zeng YY, Tang YF, Rao JH, Zhang FM, Yang SY, Wang GR, Ye LS, Lang R, Lin JH, Zheng YT, Mao YF, Zhou HK, Yan ML, Liang C, Ren SS, Wang K, Gong L, Xu S, Xu YF, Ni QQ, Wang K, Fan RF, Hu YL, Jiang T, Lin C, Gao QL, Wang ZQ, Lu YM, Zou WB, Wang X, Feng C, Wang ZC, Liu PJ, Wei WJ, Zhang F, Wu W, Lu HF, Huang JY, Liang X, Li JJ, Shan YF, Zhang XP, Cheng SQ; Chinese Association of Liver Cancer and Chinese Medical Doctor Association.
Xiang YJ, et al. Among authors: wang x.
Gut. 2026 Jul 3:gutjnl-2026-338462. doi: 10.1136/gutjnl-2026-338462. Online ahead of print.
Gut. 2026.
PMID: 42399086